Carvedilol for Prevention of Esophageal Varices Progression

• Status: Active, not recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. But the efficacy of carvedilol to delay the growth of esophageal varices in chronic hepatitis B patients was unclear.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Friendship Hospital
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• Male or Female;

• HBV-related liver cirrhotic patients with at least two years of antiviral therapy;

• The presence of small or medium esophageal varices without red color sign;

• HBV-DNA<1×10E3 IU/ml

• Signature of informed consent

Exclusion Criteria:

• Previous presence of decompensated cirrhosis including ascites, bleeding and HE (hepatic encephalopathy);

• Any contra-indications to beta-blockers including asthma, chronic obstructive pulmonary disease, allergic rhinitis, NYHA (New York Heart Association) class IV heart failure, atrioventricular block, sinus bradycardia (HR < 50 bpm), cardiogenic shock, hypotension (SBP < 90 mmHg), sick sinus syndrome, insulin dependent diabetes, peripheral vascular disease.

• Allergic to Carvedilol;

• Any malignancy that affects survival；

• Renal dysfunction；

• History of beta-blockers within last 3 months；

• History of surgery for portal hypertension；History of prior EVL (endoscopic variceal ligation) or sclerotherapy, history of surgery for portal hypertension including portosystemic shunts, disconnection and spleen resection and transjugular intrahepatic portosystemic shunt；

• Severe systemic diseases；

• Refusal to participate in the study.